{"preliminary_commentary":{"by_channel":{"x_thread":14,"podcast":3,"bluesky_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02853110\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"name":"Hypo-FLAME","nct_id":"NCT02853110","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=hypo-flame-nct02853110. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"Hypo-FLAME","arms":[{"description":"External beam radiotherapy, 5 additional MRI scans, blood sampling","label":"Hypo-FLAME","type":"EXPERIMENTAL"}],"collaborators":["The Netherlands Cancer Institute","Universitaire Ziekenhuizen KU Leuven","Radboud University Medical Center"],"completion_date":{"date":"2018-11-01","type":"ACTUAL"},"conditions":["Prostate Cancer Adenocarcinoma"],"enrollment":{"count":100,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"Hypo-FLAME study","otherNames":[],"type":"RADIATION"}],"last_update":"2018-12-20","lead_sponsor":"UMC Utrecht","official_title":"Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer (Hypo-FLAME)","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2018-11-01","type":"ACTUAL"},"primary_outcomes":[{"measure":"Acute toxicity","timeFrame":"90 days after first radiation treatment"}],"references":[{"citation":"Draulans C, Haustermans K, Pos FJ, van der Heide UA, De Cock L, van der Voort van Zyp J, De Boer H, Smeenk RJ, Kunze-Busch M, Monninkhof EM, De Roover R, Isebaert S, Kerkmeijer LGW. Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial. Radiother Oncol. 2024 Dec;201:110568. doi: 10.1016/j.radonc.2024.110568. Epub 2024 Oct 2.","pmid":"39362607","type":"DERIVED"},{"citation":"Goodman CD, Fakir H, Pautler S, Chin J, Bauman GS. Dosimetric Evaluation of PSMA PET-Delineated Dominant Intraprostatic Lesion Simultaneous Infield Boosts. Adv Radiat Oncol. 2019 Sep 27;5(2):212-220. doi: 10.1016/j.adro.2019.09.004. eCollection 2020 Mar-Apr.","pmid":"32280821","type":"DERIVED"},{"citation":"Draulans C, van der Heide UA, Haustermans K, Pos FJ, van der Voort van Zyp J, De Boer H, Groen VH, Monninkhof EM, Smeenk RJ, Kunze-Busch M, De Roover R, Depuydt T, Isebaert S, Kerkmeijer LGW. Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer. Radiother Oncol. 2020 Jun;147:92-98. doi: 10.1016/j.radonc.2020.03.015. Epub 2020 Apr 1.","pmid":"32247206","type":"DERIVED"}],"start_date":{"date":"2016-04","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer","url":"https://clinicaltrials.gov/study/NCT02853110"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/hypo-flame-nct02853110"}